Spliceosomal disruption of the non-canonical BAF complex in cancer.

Animals Cell Line, Tumor Chromatin Assembly and Disassembly / genetics Chromosomal Proteins, Non-Histone / genetics Humans Mice Neoplasm Transplantation Neoplasms / genetics Phosphoproteins / metabolism RNA Splicing RNA Splicing Factors / metabolism Spliceosomes / genetics Transcription Factors / metabolism

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
10 2019
Historique:
received: 12 01 2019
accepted: 30 08 2019
pubmed: 11 10 2019
medline: 1 4 2020
entrez: 11 10 2019
Statut: ppublish

Résumé

SF3B1 is the most commonly mutated RNA splicing factor in cancer

Identifiants

DOI: 10.1038/s41586-019-1646-9 PMID: 31597964 PMC: PMC6858563
pubmed: 31597964
doi: 10.1038/s41586-019-1646-9
pii: 10.1038/s41586-019-1646-9
pmc: PMC6858563
mid: NIHMS1538775
doi:

Substances chimiques

BRD9 protein, human 0
Chromosomal Proteins, Non-Histone 0
Phosphoproteins 0
RNA Splicing Factors 0
SF3B1 protein, human 0
Transcription Factors 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

432-436

Subventions

Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA226342
Pays : United States
Organisme : NCI NIH HHS
ID : K99 CA226342
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128239
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK103854
Pays : United States
Organisme : NIH HHS
ID : S10 OD020069
Pays : United States

Références

Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64–69 (2011).
pubmed: 21909114
Papaemmanuil, E. et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 365, 1384–1395 (2011).
pubmed: 21995386 pmcid: 3322589
Wang, L. et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365, 2497–2506 (2011).
pubmed: 22150006 pmcid: 3685413
Seiler, M., et al. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep. 23, 282–296.e284 (2018).
pubmed: 29617667 pmcid: 5933844
Alpsoy, A. & Dykhuizen, E. C. Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes. J. Biol. Chem. 293, 3892–3903 (2018).
pubmed: 29374058 pmcid: 5858003
Michel, B. C. et al. A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation. Nat. Cell Biol. 20, 1410–1420 (2018).
pubmed: 30397315 pmcid: 6698386
Gatchalian, J. et al. A non-canonical BRD9-containing BAF chromatin remodeling complex regulates naive pluripotency in mouse embryonic stem cells. Nat. Commun. 9, 5139 (2018).
pubmed: 30510198 pmcid: 6277444
Quesada, V. et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44, 47–52 (2011).
pubmed: 22158541
Furney, S. J. et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 3, 1122–1129 (2013).
pubmed: 23861464 pmcid: 5321577
Alsafadi, S. et al. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat. Commun. 7, 10615 (2016).
pubmed: 26842708 pmcid: 4743009
Harbour, J. W. et al. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat. Genet. 45, 133–135 (2013).
pubmed: 23313955 pmcid: 3789378
Martin, M. et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat. Genet. 45, 933–936 (2013).
pubmed: 23793026 pmcid: 4307600
Cretu, C. et al. Molecular architecture of SF3b and structural consequences of its cancer-related mutations. Mol. Cell 64, 307–319 (2016).
pubmed: 27720643
DeBoever, C. et al. Transcriptome sequencing reveals potential mechanism of cryptic 3′ splice site selection in SF3B1-mutated cancers. PLoS Comput. Biol. 11, e1004105 (2015).
pubmed: 25768983 pmcid: 4358997
Darman, R. B. et al. Cancer-associated SF3B1 hotspot mutations induce cryptic 3′ splice site selection through use of a different branch point. Cell Rep. 13, 1033–1045 (2015).
pubmed: 26565915
Hohmann, A. F. et al. Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition. Nat. Chem. Biol. 12, 672–679 (2016).
pubmed: 27376689 pmcid: 4990482
Gozani, O., Potashkin, J. & Reed, R. A potential role for U2AF-SAP 155 interactions in recruiting U2 snRNP to the branch site. Mol. Cell. Biol. 18, 4752–4760 (1998).
pubmed: 9671485 pmcid: 109061
Pineda, J. M. B. & Bradley, R. K. Most human introns are recognized via multiple and tissue-specific branchpoints. Genes Dev. 32, 577–591 (2018).
pubmed: 29666160 pmcid: 5959240
Remillard, D. et al. Degradation of the BAF complex factor BRD9 by heterobifunctional ligands. Angew. Chem. Int. Edn Engl. 56, 5738–5743 (2017).
Martens, J. A. & Winston, F. Recent advances in understanding chromatin remodeling by Swi/Snf complexes. Curr. Opin. Genet. Dev. 13, 136–142 (2003).
pubmed: 12672490
Brien, G. L. et al. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. eLife 7, e41305 (2018).
pubmed: 30431433 pmcid: 6277197
Moore, A. R. et al. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat. Genet. 48, 675–680 (2016).
doi: 10.1038/ng.3549 pubmed: 27089179 pmcid: 5032652
Baldi, A. et al. The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene 21, 6684–6688 (2002).
pubmed: 12242667
Chien, J. et al. Serine protease HtrA1 associates with microtubules and inhibits cell migration. Mol. Cell. Biol. 29, 4177–4187 (2009).
pubmed: 19470753 pmcid: 2715801
Walker, C. J. et al. Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA. Leukemia 33, 771–775 (2019).
pubmed: 30291333
Stein, C. A. & Castanotto, D. FDA-approved oligonucleotide therapies in 2017. Mol. Ther. 25, 1069–1075 (2017).
pubmed: 28366767 pmcid: 5417833
Pellagatti, A. et al. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. Blood 132, 1225–1240 (2018).
pubmed: 29930011 pmcid: 6172604
Smit, A., Hubley, R. & Green, P. RepeatMasker Open-4.0, http://www.repeatmasker.org (2013–2015).
Cheng, D. T. et al. Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251–264 (2015).
pubmed: 25801821 pmcid: 5808190
Seiler, M. et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat. Med. 24, 497–504 (2018).
pubmed: 29457796 pmcid: 6730556
Leeksma, A. C. et al. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. Leukemia 33, 390–402 (2019).
pubmed: 30038380
Kim, E. et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27, 617–630 (2015).
pubmed: 25965569 pmcid: 4429920
Mohammed, H. et al. Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep. 3, 342–349 (2013).
pubmed: 23403292 pmcid: 7116645
Fellmann, C. et al. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep. 5, 1704–1713 (2013).
pubmed: 24332856
Pelossof, R. et al. Prediction of potent shRNAs with a sequential classification algorithm. Nat. Biotechnol. 35, 350–353 (2017).
pubmed: 28263295 pmcid: 5416823
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
pubmed: 19910308
McCarthy, D. J., Chen, Y. & Smyth, G. K. Differential expression analysis of multifactor RNA-seq experiments with respect to biological variation. Nucleic Acids Res. 40, 4288–4297 (2012).
pubmed: 22287627 pmcid: 3378882
Wu, D. & Smyth, G. K. Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res. 40, e133 (2012).
pubmed: 22638577 pmcid: 3458527
Piva, F., Giulietti, M., Burini, A. B. & Principato, G. SpliceAid 2: a database of human splicing factors expression data and RNA target motifs. Hum. Mutat. 33, 81–85 (2012).
pubmed: 21922594
Katz, Y., Wang, E. T., Airoldi, E. M. & Burge, C. B. Analysis and design of RNA sequencing experiments for identifying isoform regulation. Nat. Methods 7, 1009–1015 (2010).
pubmed: 21057496 pmcid: 3037023
Mashtalir, N., et al. Modular organization and assembly of SWI/SNF family chromatin remodeling complexes. Cell 175, 1272–1288.e1220 (2018).
pubmed: 30343899 pmcid: 6791824
Dvinge, H. et al. Sample processing obscures cancer-specific alterations in leukemic transcriptomes. Proc. Natl Acad. Sci. USA 111, 16802–16807 (2014).
pubmed: 25385641 pmcid: 4250124
Meyer, L. R. et al. The UCSC genome browser database: extensions and updates 2013. Nucleic Acids Res. 41, D64–D69 (2013).
pubmed: 23155063
Flicek, P. et al. Ensembl 2013. Nucleic Acids Res. 41, D48–D55 (2013).
pubmed: 23203987
Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).
pubmed: 21816040 pmcid: 3163565
Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
pubmed: 19261174 pmcid: 2690996
Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-seq. Bioinformatics 25, 1105–1111 (2009).
pubmed: 19289445 pmcid: 2672628
Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).
pubmed: 20196867 pmcid: 2864565
Wagenmakers, E. J., Lodewyckx, T., Kuriyal, H. & Grasman, R. Bayesian hypothesis testing for psychologists: a tutorial on the Savage-Dickey method. Cognit. Psychol. 60, 158–189 (2010).
pubmed: 20064637
Kent, W. J. et al. The human genome browser at UCSC. Genome Res. 12, 996–1006 (2002).
pubmed: 12045153 pmcid: 186604
Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer, New York, 2016).
Zhang, Y. et al. Model-based analysis of ChIP–seq (MACS). Genome Biol. 9, R137 (2008).
pubmed: 18798982 pmcid: 2592715
The ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 (2012).
pmcid: 3439153
Huber, W. et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat. Methods 12, 115–121 (2015).
pubmed: 25633503 pmcid: 4509590
Dharmalingam G. & Carroll, T. soGGi: Visualise ChIP–seq, MNase-seq and motif occurrence as aggregate plots summarised over grouped genomic intervals. R package version 1.14.0, https://rdrr.io/bioc/soGGi/ (2018).
Yu, G., Wang, L. G. & He, Q. Y. ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics 31, 2382–2383 (2015).
pubmed: 25765347
Tan, G. & Lenhard, B. TFBSTools: an R/bioconductor package for transcription factor binding site analysis. Bioinformatics 32, 1555–1556 (2016).
pubmed: 26794315 pmcid: 4866524
Kulakovskiy, I. V. et al. HOCOMOCO: towards a complete collection of transcription factor binding models for human and mouse via large-scale ChIP-Seq analysis. Nucleic Acids Res. 46, D252–D259 (2018).
pubmed: 29140464
Robertson, A.G., et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer cell 32, 204–220.e215 (2017).
pubmed: 28810145 pmcid: 5619925
Pollard, K. S., Hubisz, M. J., Rosenbloom, K. R. & Siepel, A. Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res. 20, 110–121 (2010).
pubmed: 19858363 pmcid: 2798823
McLean, C. Y. et al. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 28, 495–501 (2010).
pubmed: 20436461 pmcid: 4840234

Auteurs

Daichi Inoue (D)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Hematology-Oncology, Institute of Biomedical Research and Innovation, Foundation for Biomedical Research and Innovation at Kobe, Kobe, Japan.

Guo-Liang Chew (GL)

Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Bo Liu (B)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Brittany C Michel (BC)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Biomedical and Biological Sciences Program, Harvard Medical School, Boston, MA, USA.

Joseph Pangallo (J)

Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Andrew R D'Avino (AR)

Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Biomedical and Biological Sciences Program, Harvard Medical School, Boston, MA, USA.

Tyler Hitchman (T)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Khrystyna North (K)

Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Department of Genome Sciences, University of Washington, Seattle, WA, USA.

Stanley Chun-Wei Lee (SC)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Lillian Bitner (L)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Ariele Block (A)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Amanda R Moore (AR)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Akihide Yoshimi (A)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Luisa Escobar-Hoyos (L)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Hana Cho (H)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Alex Penson (A)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Sydney X Lu (SX)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Justin Taylor (J)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Yu Chen (Y)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Cigall Kadoch (C)

Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Biomedical and Biological Sciences Program, Harvard Medical School, Boston, MA, USA.

Omar Abdel-Wahab (O)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. abdelwao@mskcc.org.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. abdelwao@mskcc.org.

Robert K Bradley (RK)

Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. rbradley@fredhutch.org.
Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. rbradley@fredhutch.org.
Department of Genome Sciences, University of Washington, Seattle, WA, USA. rbradley@fredhutch.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Spliceosomal disruption of the non-canonical...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Spliceosomal disruption of the non-canonical...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Assemblage et désassemblage de la chromatine › Spliceosomal disruption of the non-canonical...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Nucléoprotéines › Protéines chromosomiques nonhistones › Spliceosomal disruption of the non-canonical...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Spliceosomal disruption of the non-canonical...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Spliceosomal disruption of the non-canonical...
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Spliceosomal disruption of the non-canonical...
questionsmedicales.fr › Tumeurs › Spliceosomal disruption of the non-canonical...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Phosphoprotéines › Spliceosomal disruption of the non-canonical...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Maturation post-transcriptionnelle des ARN › Épissage des ARN › Spliceosomal disruption of the non-canonical...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Nucléoprotéines › Protéines de liaison à l'ARN › Facteurs d'épissage des ARN › Spliceosomal disruption of the non-canonical...
questionsmedicales.fr › Cellules › Structures cellulaires › Espace intracellulaire › Structures nucléaires › Espace intranucléaire › Splicéosomes › Spliceosomal disruption of the non-canonical...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Spliceosomal disruption of the non-canonical...